AzTrials
AzTrials

LymphomaPhase 2LYM-2023NCT00509379

Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

A Phase 2 study testing Rituximab and VELCADE in people with Lymphoma and Non-Hodgkin Lymphoma, run by Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie at 22 sites in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The promising activity of Bortezomib as single agent in low grade lymphoma patients in small studies has led to a number of larger multicenter trials with Bortezomib in combination with Rituximab in mantle-cell lymphoma, follicular lymphoma and marginal zone lymphoma. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Lymphoma, Non-Hodgkin Lymphoma
What is being tested?
Rituximab and VELCADE
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
22 sitesItaly
Study dates
Sep 2006to Jan 2011
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with naïve or sensitive rituximab indolent non-follicular and mantle cell non-Hodgkin's Lymphoma disease that had failed to respond or relapsed after primary therapy. There is a demonstrated progressive disease requiring further treatment. Histological subtype included into the study are are as follows Small lymphocytic/lymphoplasmocytic lymphoma; Nodal marginal zone Lymphoma (MALT lymphoma are excluded) Splenic marginal zone lymphoma Mantle cell lymphoma A lymphnode biopsy is advisable if it is not harmful for the patients, before enrollment of the patient into the study in order to confirm diagnosis and to rule out histologic transformation. Lymphnode biopsy should be performed within 6 months before study entry.
  • Age >18-75
  • Relapse or failure to respond after one or more (maximum three) lines of chemotherapy
  • Any type of prior chemotherapy, rituximab included. Patients who had received high dose chemotherapy and ASCT can be enrolled into the study
  • Naïve or sensitive rituximab disease. If the patient received Rituximab, he/she must have responded and the TTP from the last dose to rituximab must have been 6 months or more.
  • Measurable and/or evaluable disease.
Show all 14Show fewer
  • Adequate haematological counts: ANC> 1.0 x 109/L and PLT counts> 75 x 109/L unless due to bone marrow involvement by lymphoma.
  • Conjugated bilirubin up to 2 x ULN.
  • Alkaline phosphatase and transaminases up to 2 x ULN.
  • Creatinine clearances> 30 m/min.
  • Non peripheral neuropathy or CNS disease.
  • Life expectancy> 6 months.
  • Performance status< 2 according to ECOG scale.
  • Written informed Consent

Who cannot join

  • Has known or suspected hypersensitivity or intolerance to rituximab, boron, mannitol, or heparin, if an indwelling catheter is used
  • History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
  • Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug
  • Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 5, NYHA Classification of Cardiac Disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
  • History of hypotension or has decreased blood pressure (sitting systolic blood pressure SBP 100 mmHg and/or sitting diastolic blood pressure DBP 60 mmHg)
  • Pregnant or breastfeeding
Show all 15Show fewer
  • Peripheral Neuropathy or Neuropathic Pain Grade 2
  • HIV positivity
  • HBV positivity with the exception of patients with HBVcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative
  • HCV positivity with the exception of patients with no signs of active chronic hepatitis histologically confirmed
  • Active opportunistic infection
  • Receipt of extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy within 4 weeks before enrollment
  • Exposure to Rituximab within 24 weeks before screening
  • Have received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
  • Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

Trial locations and contacts

22 sites in 1 country.

22 sites in 1 country

Italy22 sites

  • ASO SS Antonio e Biagio e Cesare Arrigo

    Alessandria

  • Ospedale Oncologico

    Bari

  • Policlinico S.Orsola Malpighi

    Bologna

  • Spedali Civili

    Brescia

  • Ospedale Armando Businco

    Cagliari

  • Istituto per la ricerca e la cura del cancro

    Candiolo, Torino

  • Ospedale Civico

    Chivasso, Torino

  • Stabilimento Ospedaliero

    Cirié, Torino

  • ASO S. Croce e Carle

    Cuneo

  • Az. Ospedaliero Universitaria Careggi

    Florence

  • IRCCS San Raffaele

    Milan

  • Ospedale Cà Granda Niguarda

    Milan

  • Univ. Studi Federico II

    Naples

  • ASO Maggiore della Carità Ematologia

    Novara

  • Policlinico Monteluce

    Perugia

  • Ospedale Bianchi-Melacrino-Morelli

    Reggio Calabria

  • Università La sapienza Policlinico Umberto I

    Roma

  • Istituto Clinico Humanitas

    Rozzano, Milano

  • Spedali Riuniti

    Siena

  • ASO San Giovanni Battista SC Ematologia 2

    Torino

  • Ospedale Cardinale Panico

    Tricase, Lecce

  • Policlinico Universitario

    Udine

Other trials in Italy

About this study

Official title: A Phase II Multicenter Non-randomized Study to Assess Safety, Toxicity and Clinical Activity of the Association of Bortezomib(VELCADE)With Rituximab in Relapsed/Refractory Indolent Non Follicular and Mantle-cell Non-Hodgkin Lymphoma

The promising activity of Bortezomib as single agent in low grade lymphoma patients in small studies has led to a number of larger multicenter trials with Bortezomib in combination with Rituximab in mantle-cell lymphoma, follicular lymphoma and marginal zone lymphoma.

Read the detailed description

This is a open label, non randomized, phase II , multicenter, prospective trial to evaluate the efficacy and safety of the combination of bortezomib and rituximab in patients with relapsed or refractory rituximab naïve or sensitive indolent non-follicular and mantle cell non-Hodgkin's lymphoma. Despite of the availability of treatment for this disease, this study is justified because no known therapies are really curative and it is necessary to look for new treatment options to improve the clinical outcome and prognosis of relapsed indolent lymphoma. This study is designed for patients not eligible for high-dose chemotherapy and autologous stem cells transplantation.

Being tested
Rituximab, VELCADE
Keywords
Relapsed/refractory indolent lymphoma, Non-follicular Lymphoma, Mantle cell non-Hodgkin Lymphoma, Patients naïve or sensitive to rituximab, Patients not eligible for high dose chemotherapy with ASCT
Medical subject headings
Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RituximabDrug

    Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.

  • VELCADEDrug

    VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.

Study groups in NCT00509379
Study groupRoleWhat they receive
1ExperimentalAll patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
Receives: Drug: Rituximab; Drug: VELCADE

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To demonstrate a statistical benefit in overall response rate (ORR) of the Bortezomib/Rituximab association in this study 3/13 or fewer responses are observed during the first stage then the trail is stopped early

    Measured: 1 year

Secondary outcomes (1)

  1. If 12/43 or fewer responses are observed by the end of the trail, then no further investigation of this regimen is warranted

    Measured: 4 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2007 (estimated)
  2. Study startSep 2006
  3. Primary completionNov 2007
  4. Study completionJan 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
48 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00509379
Sponsor's protocol ID
BRIL06
Other IDs
LYM-2023
Acronym
LYM-2023
Status last verified
Jul 2009
First submitted
30 Jul 2007
Last updated
28 Jan 2011
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Rituximab and VELCADE in people with Lymphoma and Non-Hodgkin Lymphoma, run by Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie at 22 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jan 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 22 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To demonstrate a statistical benefit in overall response rate (ORR) of the Bortezomib/Rituximab association in this study 3/13 or fewer responses are observed during the first stage then the trail is stopped early (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00509379.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2011.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in